Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3

Status

Unknown 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Lymphoid 1Gastrointestinal 1

Conditions

Neoplasms 8Melanoma 6Carcinoma, Non-Small-Cell Lung 5Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Stomach Neoplasms 3Neoplasm Metastasis 3Lymphoma 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Nasopharyngeal Carcinoma 2Liver Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Renal Cell 2Advanced Solid Tumors 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Solid Tumor 1Skin Neoplasms 1Sarcoma 1Primary Condition: Advanced Tumors 1Neuroendocrine Tumors 1Mouth Neoplasms 1Lung Neoplasms 1Locoregionally Advanced Laryngo-hypopharyngeal Squamous Cell Cancer 1Kidney Neoplasms 1High-Risk Resectable NSCLC 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 58Gemcitabine 37Biopsy 33Specimen Handling 32Paclitaxel 30Magnetic Resonance Spectroscopy 30Nivolumab 29Cisplatin 25Irinotecan 24Carboplatin 24Cyclophosphamide 23Fluorouracil 22Bevacizumab 22Docetaxel 21Oxaliplatin 19Leucovorin 18Ipilimumab 17Cetuximab 17Capecitabine 17130-nm albumin-bound paclitaxel 16Everolimus 15Albumin-Bound Paclitaxel 15Trastuzumab 13olaparib 12Pemetrexed 12Erlotinib Hydrochloride 12spartalizumab 11Sorafenib 11Radiosurgery 11trastuzumab deruxtecan 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm Metastasis × toripalimab × Clear all
NCT06657144 2026-04-06

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Coherus Oncology, Inc.

Phase 1 Recruiting
154 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04137900 2024-02-05

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

TopAlliance Biosciences

Phase 1 Unknown
499 enrolled
DermatologicLymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma, Neoplasm Metastasis

NCT04072900 2020-04-28

A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma

Xiangya Hospital of Central South University

Phase 1 Unknown
30 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡